GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (NAS:IBRX) » Definitions » ROC (Joel Greenblatt) %

ImmunityBio (ImmunityBio) ROC (Joel Greenblatt) % : -434.79% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is ImmunityBio ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. ImmunityBio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -434.79%.

The historical rank and industry rank for ImmunityBio's ROC (Joel Greenblatt) % or its related term are showing as below:

IBRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -319.27   Med: -241.84   Max: -229.26
Current: -238.75

During the past 5 years, ImmunityBio's highest ROC (Joel Greenblatt) % was -229.26%. The lowest was -319.27%. And the median was -241.84%.

IBRX's ROC (Joel Greenblatt) % is ranked better than
55.41% of 1469 companies
in the Biotechnology industry
Industry Median: -336.59 vs IBRX: -238.75

ImmunityBio's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


ImmunityBio ROC (Joel Greenblatt) % Historical Data

The historical data trend for ImmunityBio's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunityBio ROC (Joel Greenblatt) % Chart

ImmunityBio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
- -239.26 -319.27 -229.26 -244.41

ImmunityBio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -174.12 -179.03 -216.06 -127.00 -434.79

Competitive Comparison of ImmunityBio's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, ImmunityBio's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ImmunityBio's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmunityBio's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where ImmunityBio's ROC (Joel Greenblatt) % falls into.



ImmunityBio ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 22.961) - (69.993 + 0 + 15.968)
=-63

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 24.454) - (34.732 + 0 + 18.307)
=-28.585

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of ImmunityBio for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-805.312/( ( (187.81 + max(-63, 0)) + (182.625 + max(-28.585, 0)) )/ 2 )
=-805.312/( ( 187.81 + 182.625 )/ 2 )
=-805.312/185.2175
=-434.79 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ImmunityBio  (NAS:IBRX) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


ImmunityBio ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of ImmunityBio's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmunityBio (ImmunityBio) Business Description

Traded in Other Exchanges
Address
3530 John Hopkins Court, San Diego, CA, USA, 92121
ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. Geographically, the company operates in United States and Europe. Majority of the revenue is generated from Europe.
Executives
Patrick Soon-shiong director, 10 percent owner, officer: See remarks 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
California Capital Equity, Llc 10 percent owner 10182 CULVER BOULEVARD, CULVER CITY CA 90232
Nant Capital, Llc 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Cambridge Equities, Lp 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Mp 13 Ventures, Llc 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Michael D Blaszyk director C/O NANTKWEST, INC., 2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
John Owen Brennan director C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Wesley Clark director C/O ARGYLE SECURITY ACQUISITION CORP., 200 CONCORD PLAZA, SUITE 700, SAN ANTONIO TX 78216
Regan J Lauer officer: Chief Accounting Officer 4250 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA 92037
Richard Adcock officer: Chief Executive Officer C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Cheryl Cohen director C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Linda Maxwell director 1040 SPRING STREET, SILVER SPRING NC 27709
Christobel Selecky director C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
David C. Sachs officer: Chief Financial Officer C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Frederick W Driscoll director

ImmunityBio (ImmunityBio) Headlines

From GuruFocus